Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559310 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
A Phase 3 study, sponsored by Nabriva Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 551
- Enrollment target
NCT02559310 is a Phase 3 study that has completed, run by Nabriva Therapeutics. The registered enrollment target is 551 participants.
The verdict
NCT02559310, a Phase 3 study, has completed, sponsored by Nabriva Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 551 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
Interventions
- DRUG Moxifloxacin
- DRUG Linezolid
- DRUG lefamulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02559310
The ClinicalTrials.gov registry entry for NCT02559310 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 551 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabriva Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT02559310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02559310 about?
NCT02559310 is a clinical study titled "Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia". This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
What is the current status of trial NCT02559310?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 551 participants. The study started on 2015-09. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02559310?
The interventions under investigation include: Moxifloxacin (DRUG), Linezolid (DRUG), lefamulin (DRUG).
Who is sponsoring clinical trial NCT02559310?
This trial is sponsored by Nabriva Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.